Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Cigall Kadoch
Dana Farber Cancer Inst, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Foghorn Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Please see attachment.
Cancer-Specific Targeting and Function of Mammalian SWI/SNF (BAF) Chromatin Remodeling Complexes
PROJECT NARRATIVE Human synovial sarcoma is an aggressive soft-tissue malignancy uniformly driven by the t(X;18) chromosomal translocation which produces the SS18-SSX fusion oncoprotein, the hallmark molecular feature of nearly 100% of cases. SS18-SSX incorporates in to mammalian SWI/SNF (BAF) chromatin remodeling complexes, altering their localization genome-wide. This proposal aims to identify the mechanisms by which SS18-SSX alters the targeting of BAF complexes on chromatin to affect global gene expression and support oncogenic cellular proliferation, providing a foundation for the identification of new strategies toward therapeutic intervention.
Filed on May 07, 2019.
Tell us what you know about Cigall Kadoch's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Cigall Kadoch filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | $200,000 - $249,999 |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics, Inc. | $150,000 - $199,999 |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | $150,000 - $199,999 |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | $0 - $4,999 |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics, Inc. | Value cannot be readily determined |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics | Value cannot be readily determined |
| Cigall Kadoch | Dana Farber Cancer Inst | Conflict of Interest | Foghorn Therapeutics, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.